Sources and Guidelines Referenced

European Association of Urology (EAU) Guidelines on Prostate Cancer (2024); National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 2.2024); American Urological Association / American Society for Radiation Oncology (AUA/ASTRO) Guidelines (2023); ProtecT Clinical Trial 15-Year Outcomes (Hamdy et al., NEJM 2023); PIVOT Trial 10-Year Follow-up (Wilt et al., NEJM 2017); Anatomical Nerve-Sparing Radical Prostatectomy Standards (Walsh et al., Journal of Urology).

Prostate Cancer Surgery: A Comprehensive Patient Guide

1. Definition and Medical Identity

Prostate cancer surgery, known formally as radical prostatectomy, is the complete surgical removal of the prostate gland, seminal vesicles, and adjacent tissues. It is a primary curative surgical operation performed within surgical uro-oncology to eradicate localized prostate malignancy before the cancer metastasizes to regional lymph nodes or distant bones.

The surgery involves disconnecting the prostate from the urinary bladder neck above and the membranous urethra below. Once the organ is excised, surgeons perform a vesicourethral anastomosis, which is the direct surgical reconnection of the bladder neck to the urethral stump. Depending on patient-specific risk factors, clinicians may also perform a pelvic lymph node dissection (PLND) to remove regional lymph nodes for accurate cancer staging.

2. The Underlying Condition or Need

Prostate cancer develops when epithelial cells within the prostate gland undergo genetic alterations, leading to uncontrolled cellular proliferation and tumor formation. In its early stages, prostate adenocarcinoma is confined within the fibrous prostatic capsule. If left untreated, aggressive clones can breach the capsule, invade adjacent structures like the seminal vesicles, and spread via lymphatic channels or blood vessels to pelvic lymph nodes and the axial skeleton.

The disease frequently produces no noticeable physical symptoms during early, localized development. As the tumor grows, patients may experience lower urinary tract symptoms, including a weak urinary stream, frequency, nocturia (waking at night to urinate), or hematuria (blood in the urine). Surgery is indicated to physically eliminate the primary tumor burden, halting local progression and preventing distant metastatic spread (NCCN Guidelines 2024).

3. How the Treatment Works — Mechanism

Prostate cancer surgery works via total anatomical extirpation—physically removing every millimeter of internal prostatic tissue containing malignant cells. By extirpating the primary site, the body is cleared of active cancer cell replication, preventing further localized invasion or hematogenous seeding.

From a biological standpoint, surgical removal eliminates the source of prostate-specific antigen (PSA), a protein produced naturally by prostatic glandular tissue. Following a successful complete resection, serum PSA levels drop to zero or undetectable levels (typically below 0.1 ng/mL) within 4 to 6 weeks. This biological clearance serves as an unambiguous biomarker for treatment success. Anatomically, surgeons carefully isolate delicate cavernous nerve bundles (the neurovascular bundles) running adjacent to the prostatic capsule to preserve penile erectile response, provided doing so does not compromise cancer excision margins (Walsh et al.).

4. Types and Variations

Prostate cancer surgery can be performed using three primary surgical modalities: robot-assisted laparoscopic radical prostatectomy, conventional laparoscopic radical prostatectomy, and open radical prostatectomy. The choice depends on surgeon expertise, anatomical considerations, patient health, and equipment availability.

Surgical Variation	Technique Description	Invasiveness	Typical Hospital Stay	Key Clinical Considerations
Robot-Assisted Laparoscopic (RARP)	Uses 3D high-definition visualization and robotic wristed instruments controlled by a surgeon at a console.	Minimally Invasive (5–6 small incisions)	1 to 2 days	Reduced blood loss, shorter hospital stay, faster early functional recovery; current standard of care in developed healthcare systems (EAU 2024).
Laparoscopic Radical Prostatectomy (LRP)	Uses standard rigid laparoscopic instruments and a video camera inserted through abdominal ports.	Minimally Invasive (4–5 small incisions)	1 to 2 days	Requires high technical expertise; lower blood loss than open, but lacks 3D depth perception and flexible wrist articulation.
Open Retropubic Radical Prostatectomy (RRP)	Direct physical access through a single lower abdominal midline incision without entering the peritoneal cavity.	Open Surgical Procedure	2 to 4 days	Tactile tissue feedback; higher risk of intraoperative blood loss; effective alternative when robotic technology is unavailable or contraindicated.
Open Perineal Radical Prostatectomy (PRP)	Incision made between the scrotum and anus directly overlying the prostate apex.	Open Surgical Procedure	1 to 3 days	Lower blood loss; highly difficult to perform concomitant pelvic lymph node dissection through the same operative window.

5. Who the Treatment Is For — Indications

Prostate cancer surgery is indicated primarily for men diagnosed with biopsy-confirmed, non-metastatic prostate cancer who have a projected life expectancy exceeding 10 years (EAU Guidelines 2024). Candidates undergo comprehensive diagnostic workup, including multiparametric magnetic resonance imaging (mpMRI), prostate tissue biopsy, and systemic staging scans for high-risk profiles.

• Low-Risk Localized Disease: ISUP Grade Group 1 (Gleason 3+3=6), PSA under 10 ng/mL, stage T1c–T2a, reserved for young patients or those uncomfortable with active surveillance.
• Favorable and Unfavorable Intermediate-Risk Disease: ISUP Grade Group 2 or 3 (Gleason 3+4=7 or 4+3=7), PSA 10–20 ng/mL, or stage T2b–T2c; surgery represents a gold-standard primary curative therapy.
• High-Risk Localized Disease: ISUP Grade Group 4 or 5 (Gleason 8–10), PSA over 20 ng/mL, or stage T3a; surgery is offered as part of a multimodal treatment plan combining surgery, extended pelvic lymph node dissection, and potential postoperative adjuvant radiation.
• Salvage Radical Prostatectomy: Indicated for localized disease recurrence following failure of primary radiation therapy, provided no distant metastases are present.

6. Who the Treatment Is Not For — Contraindications

Not all prostate cancer patients are suitable candidates for surgical intervention. Surgery is contraindicated when the procedure carries unacceptable operative mortality risks or when the cancer has spread beyond curative surgical boundaries.

• Absolute Contraindications: Documented distant osseous or visceral metastases (Stage M1); uncorrectable severe coagulopathies or bleeding disorders; severe acute cardiopulmonary instability precluding general anesthesia.
• Relative Contraindications: Projected life expectancy under 10 years due to advanced age or severe comorbidities (where non-invasive management or active surveillance is clinically preferred); extensive prior pelvic radiation or major frozen pelvic surgery causing severe fibrosis; active severe urinary tract infections (surgery delayed until resolved).

7. Alternatives and Clinical Comparison

Patients with localized prostate cancer have multiple evidence-based options. Selecting between surgery, radiation, or active surveillance depends on tumor risk group, baseline urinary and erectile function, overall health status, and personal patient priorities regarding side-effect profiles.

rest>No procedural impact on bowel function.

Treatment Alternative	Primary Mechanism	Level of Invasiveness	Impact on Urinary Function	Impact on Sexual Function	Impact on Bowel Function
Radical Prostatectomy	Complete surgical removal of the prostate gland.	Surgical (Minimally invasive or open)	Temporary or persistent stress incontinence; minimal irritative symptoms.	Immediate risk of erectile dysfunction; gradual recovery over 12–24 months if nerve-sparing.	No significant impact on bowel function.
External Beam Radiation (EBRT)	High-energy x-ray beams targeted to destroy cellular DNA within the prostate.	Non-Invasive (Multiple outpatient visits)	Low short-term incontinence; potential late radiation cystitis and irritative storage symptoms.	Progressive decline in erectile function over 2 to 5 years post-treatment.	Risk of radiation proctitis, rectal bleeding, and bowel urgency.
Brachytherapy	Permanent radioactive seeds (LDR) implanted directly into prostatic tissue.	Minimally Invasive (Perineal needle insertion)	Risk of urinary retention, dysuria, and lower urinary tract swelling.	Moderate decline in erectile function over time; lower initial rate than surgery.	Low risk of localized rectal irritation.
Active Surveillance	Rigorous ongoing monitoring with PSA tests, MRI, and periodic repeat biopsies.	Non-Invasive (Diagnostic oversight)	No procedural impact on baseline urinary function.	No procedural impact on baseline sexual function.

8. Pre-Treatment Phase

The pre-treatment phase begins once a tissue biopsy confirms prostate cancer. Clinicians establish tumor risk stratification using multiparametric MRI (mpMRI) and bone scans or PSMA-PET/CT scans for high-risk cases to verify that disease remains localized within the prostate (EAU Guidelines 2024).

Patients undergo thorough pre-operative medical clearance, including blood counts, kidney function tests, electrocardiograms (ECG), and pulmonary evaluations. Medications influencing blood clotting—such as aspirin, clopidogrel, warfarin, or direct oral anticoagulants—are carefully stopped under physician direction 5 to 7 days prior to surgery. Patients are instructed on pre-operative pelvic floor muscle training (Kegel exercises), which accelerates the recovery of urinary continence post-catheter removal. On the day prior to surgery, a light clear-liquid diet and gentle oral bowel preparation are administered, followed by strict oral intake restriction (fasting) after midnight.

9. The Procedure — Step-by-Step Clinical Detail

Prostate cancer surgery is performed under general anesthesia in a sterile operating theater. The procedure takes between 2 to 4 hours depending on anatomical complexity and surgical approach.

• Step 1: Patient Positioning and Access: The patient is placed in a steep Trendelenburg position (head down) for robotic/laparoscopic approaches. Small abdominal port incisions are made, and carbon dioxide gas is insufflated to create an operative working space.
• Step 2: Exposure of the Retropubic Space: The parietal peritoneum is incised, and the urinary bladder is gently mobilized away from the anterior abdominal wall to expose the prostate gland and retropubic space (Space of Retzius).
• Step 3: Endopelvic Fascia Incision and Dorsal Venous Complex Control: The endopelvic fascia covering the levator ani muscle is opened. The dorsal venous complex—a major bundle of blood vessels overlying the prostate apex—is suture-ligated or clipped to control bleeding.
• Step 4: Bladder Neck Transection: The boundary between the bladder base and the top of the prostate (bladder neck) is carefully identified and divided. The prostatic urethra is exposed and transected at the base.
• Step 5: Seminal Vesicle and Vas Deferens Dissection: The paired vas deferens are identified, clipped, and divided. The seminal vesicles located posterior to the bladder are completely mobilized away from the anterior rectal wall.
• Step 6: Neurovascular Bundle Dissection (Nerve-Sparing): If nerve-sparing is planned, surgeons use delicate sharp dissection to detach the cavernous nerve sheets from the dorsolateral surface of the prostate capsule, avoiding thermal energy to prevent nerve damage.
• Step 7: Apical Dissection and Urethral Division: The prostate apex is dissected free from the striated urethral sphincter. The urethra is transected, leaving maximum functional urethral length, and the prostate specimen is removed in an retrieval bag.
• Step 8: Pelvic Lymph Node Dissection (if indicated): Regional obturator and external iliac lymph nodes are dissected out and submitted for frozen or permanent histopathology.
• Step 9: Vesicourethral Anastomosis: A multi-strand running suture line joins the open bladder neck directly to the urethral stump over a newly placed indwelling silicone Foley catheter, restoring urinary continuity. The surgical field is inspected, abdominal ports are closed, and a temporary surgical drain may be left in the pelvis.

10. Immediate Post-Procedure Period

Immediately following surgery, the patient is transferred to the Post-Anesthesia Care Unit (PACU) for close monitoring of vital signs, fluid balance, and pain control. Once fully conscious and stable, the patient is transferred to an inpatient surgical ward.

Early post-operative care emphasizes early mobilization; patients are encouraged to sit upright and walk within 12 to 24 hours to reduce the risk of deep vein thrombosis (DVT) and facilitate bowel motility. Multimodal analgesia—utilizing oral acetaminophen, non-steroidal anti-inflammatory drugs, and minimal short-acting opioids—ensures comfortable pain control. The surgical drain, if placed, is typically monitored for output and removed within 24 to 48 hours. Patients are educated on indwelling urinary catheter hygiene, leg bag maintenance, and home care prior to discharge, which usually occurs on post-operative day 1 or 2.

11. Recovery — Short and Long Term

Recovery from radical prostatectomy proceeds through distinct physiological phases over the first post-operative year, focusing on anatomical tissue healing and functional neural regeneration.

During weeks 1 to 2, the primary focus is managing the indwelling urinary catheter. At 7 to 14 days post-surgery, a cystogram or routine trial of void is conducted in the clinic, and the catheter is removed. Immediate urinary leakage (stress incontinence) is universal upon catheter removal due to temporary sphincter stunning and urethral swelling. Patients wear protective absorbent pads and perform pelvic floor muscle exercises daily.

By weeks 4 to 6, incision sites are fully healed, and patients may resume light activities, non-strenuous work, and driving, while avoiding heavy lifting (>10 lbs) to prevent incisional hernia formation. Over months 3 to 12, urinary continence improves significantly, with approximately 85% to 95% of men achieving continent status (defined as zero pads or one safety pad per day) by 12 months (EAU Guidelines 2024). Erectile function recovery occurs much more slowly over 6 to 24 months, as microvascular blood flow and nerve axon regeneration progress gradual neuro-rehabilitation.

12. Risks, Side Effects, and Complications

While radical prostatectomy is an established, safe procedure, surgical risks exist ranging from minor post-operative inconveniences to serious long-term functional alterations.

Complication Category	Clinical Manifestation	Approximate Frequency	Management Strategy
Common / Expected Side Effects	Transient urinary stress incontinence; temporary erectile dysfunction; minor incisional discomfort; blood-tinged urine during early catheter phase.	High (>50% initially)	Pelvic floor muscle training (Kegels); protective pads; phosphodiesterase-5 inhibitors (PDE5-i); clinical reassurance.
Uncommon Complications	Symptomatic urinary tract infection (UTI); urinary anastomotic leak; pelvic lymphocele formation; delayed wound healing; urethral stricture.	Moderate (2% to 10%)	Targeted oral antibiotics; prolonged catheter drainage; image-guided fluid aspiration; endoscopic urethral dilation.
Rare / Serious Complications	Rectal injury/fistula; severe intraoperative hemorrhage requiring transfusion; deep vein thrombosis (DVT) / pulmonary embolism (PE); obturator nerve injury.	Low (<2%)	Primary intraoperative repair; blood transfusions; systemic anticoagulation; open or laparoscopic revision.

13. Lifestyle and Behavioural Considerations

Optimizing health habits before and after prostate cancer surgery directly influences functional recovery timelines and overall cardiovascular wellness.

Prior to surgery, patients should cease all tobacco use at least 4 weeks in advance, as nicotine impairs microvascular oxygenation and significantly increases the risk of anastomotic breakdown, wound infection, and pulmonary complications. Consuming a balanced, fiber-rich diet and maintaining adequate hydration prevents constipation, preventing post-operative straining that exerts dangerous pressure on the healing vesicourethral anastomosis. Following catheter removal, avoiding bladder irritants such as excessive caffeine, alcohol, highly acidic foods, and artificial sweeteners helps minimize urinary urgency and frequency during early pelvic floor recovery.

14. How Outcomes Are Measured

Oncological success following radical prostatectomy is defined primarily by definitive histological surgical margin evaluation and post-operative biochemical tracking. The resected prostate is sent to pathology, where pathologists measure tumor volume, pathological Gleason score, organ-confined status (pT stage), and surgical margin involvement.

Biochemical monitoring begins 4 to 6 weeks after surgery with a serum PSA blood test. An undetectable PSA level (defined as <0.1 ng/mL or <0.02 ng/mL on ultra-sensitive assays) confirms complete clearance of prostate tissue. Biochemical recurrence (BCR) is clinically defined by EAU and AUA criteria as two consecutive rising serum PSA values of 0.2 ng/mL or greater. Functional outcomes are measured using validated patient-reported outcome measures, such as the Expanded Prostate Cancer Index Composite (EPIC), evaluating urinary continence and sexual function recovery scores over 24 months.

15. Recent Advances and Current Standard of Care

Over the past decade, the standard of care for prostate cancer surgery has transitioned firmly toward robot-assisted laparoscopic radical prostatectomy (RARP), which now accounts for the majority of procedures performed in high-resource medical centers worldwide.

Advances in imaging—particularly modern 68Ga-PSMA or 18F-DCFPyL PET/CT scans—allow highly sensitive pre-operative detection of occult nodal metastases, refining surgical candidate selection (EAU Guidelines 2024). Intraoperative innovations include the use of real-time neurovascular bundle preservation techniques, firefly fluorescence imaging using indocyanine green (ICG) to assess tissue perfusion and identify lymphatic drainage pathways, and single-port (SP) robotic systems that allow the entire operation to be conducted through a single 2.5 cm umbilical incision.

16. Common Myths and Misconceptions

Misinformation regarding prostate cancer surgery often causes unnecessary anxiety regarding recovery expectations and functional outcomes.

Myth: Prostate cancer surgery instantly causes permanent, total urinary incontinence in all men.
Reality: While temporary leakage occurs immediately after catheter removal, 85% to 95% of men regain functional urinary continence within 12 months post-surgery when performing guided pelvic floor exercises (EAU 2024).

Myth: Nerve-sparing surgery guarantees that erectile function will remain completely unchanged immediately after the operation.
Reality: Surgical manipulation causes temporary nerve stunning (neuropraxia). Even with complete bilateral nerve preservation, erectile recovery requires 6 to 24 months of gradual nerve healing and penile rehabilitation.

Myth: If the prostate is removed, a man can still ejaculate normally during sexual climax.
Reality: Radical prostatectomy removes the prostate and seminal vesicles, which produce seminal fluid. Following surgery, climax produces an orgasm without fluid release, known as a dry ejaculate.

Myth: Robotic prostatectomy is performed autonomously by a computer program without human intervention.
Reality: Robotic systems are entirely master-slave devices; every micro-movement of the robotic instruments is controlled in real-time by an experienced urologic surgeon sitting at the surgical console.

Myth: Surgery is always vastly superior to radiation therapy for long-term survival in localized prostate cancer.
Reality: Major multi-center clinical trials, including the 15-year ProtecT study (Hamdy et al., NEJM 2023), demonstrate equivalent overall and prostate-cancer-specific survival rates between radical prostatectomy and radiation therapy for localized disease.

Myth: A elevated PSA level after surgery means the cancer has metastasized everywhere in the body.
Reality: A detectable PSA indicates biochemical recurrence, but modern PSMA-PET imaging can localize microscopic recurrent tissue early, allowing effective localized salvage radiation therapy.

17. Frequently Asked Questions

How long will I need to wear a urinary catheter after prostate cancer surgery?

An indwelling urinary catheter remains in place for 7 to 14 days following surgery. This tube allows urine to drain continuously into an external collection bag while the delicate surgical join between the bladder neck and the urethra heals cleanly. The catheter is removed during an outpatient office visit after healing is confirmed.

When can I return to work and normal physical activities?

Most patients return to light desk work and sedentary daily routines within 2 to 3 weeks after surgery. However, strenuous physical exertion, heavy lifting over 10 pounds, vigorous exercise, and bicycle riding must be avoided for 6 weeks to prevent pelvic bleeding, strain on the healing urinary join, and abdominal hernia formation.

What is a nerve-sparing radical prostatectomy?

Nerve-sparing radical prostatectomy is a delicate surgical technique where the surgeon carefully detaches and preserves the microscopic neurovascular bundles that run along the sides of the prostate gland. These nerves control penile erections. Nerve-sparing is performed whenever tumor boundaries allow safe removal without leaving cancer cells behind behind on the margin.

Will I still be able to have an orgasm after prostate surgery?

Yes, climax and orgasm are neurological responses managed by nerve pathways distinct from those controlling fluid ejaculation. Patients can still experience pleasurable orgasmic sensations after prostate surgery, though the climax will be dry because the prostate gland and seminal vesicles—which generate semen—have been completely excised.

How soon will I know if the surgery successfully removed all the cancer?

Definitive initial confirmation comes from the final pathology report, available approximately 7 to 10 days after surgery. This report examines the tumor edges (surgical margins). The ultimate biological confirmation occurs 4 to 6 weeks post-operatively through a blood test showing an undetectable serum PSA level (less than 0.1 ng/mL).

What happens if my PSA rises after surgery?

A rising PSA level after surgery is called biochemical recurrence. If this occurs, your clinician will order advanced staging imaging, such as a PSMA-PET scan, to locate the source. Treatment options for post-surgical PSA recurrence include localized salvage radiation therapy to the prostatic bed, often combined with temporary androgen deprivation therapy.

Is robot-assisted surgery safer than open surgery?

Both robot-assisted and open prostatectomies achieve excellent, comparable long-term cancer cure rates when performed by expert urologists. However, robot-assisted surgery typically results in significantly less intraoperative blood loss, lower transfusion rates, less post-operative pain, smaller abdominal surgical scars, and a slightly shorter hospital stay compared to open surgery.

Will prostate surgery shorten my penis?

Some men experience a slight reduction in apparent penile length (typically 0.5 to 1.5 cm) following radical prostatectomy. This occurs due to anatomical shortening of the urethral segment during reconnection and temporary tissue retraction. Penile rehabilitation therapy and early nerve recovery help minimize long-term structural changes.

How does pelvic floor exercise help after prostate surgery?

Pelvic floor muscle training strengthens the external urethral sphincter muscle, which surrounds the membranous urethra. Because the internal urethral sphincter at the bladder neck is removed during surgery, strengthening the external sphincter through regular exercises helps prevent urinary leakage and dramatically accelerates the recovery of continence.

Can prostate cancer recur years after a successful surgery?

Yes, microscopic cancer cells present outside the prostate prior to surgery can slowly proliferate years later, causing a delayed rise in PSA levels. This is why long-term annual PSA monitoring is recommended for at least 10 years following radical prostatectomy, even if early blood tests show zero PSA.

What is penile rehabilitation, and when does it begin?

Penile rehabilitation involves using medications (such as daily low-dose PDE5 inhibitors) or vacuum erection devices post-operatively to promote blood flow and tissue oxygenation to the erectile tissues. It typically begins shortly after catheter removal to preserve cavernous tissue health while resected neurovascular bundles gradually regenerate over 12 to 24 months.

Why do I need a drain in my abdomen after surgery?

A temporary abdominal drain is placed during surgery to collect minor blood, lymphatic fluid, or residual irrigating fluid from the pelvic operative space. It prevents fluid accumulation (seroma or lymphocele formation) that could press on internal organs or cause infection, and is usually removed within 24 to 48 hours before discharge.

How does age affect the decision to have prostate cancer surgery?

Surgical decision-making depends more on overall physical health, cardiopulmonary fitness, and overall life expectancy than chronological age alone. Standard guidelines recommend surgery for patients with localized disease and a life expectancy of 10 years or more, ensuring that the oncological benefits of surgery outweigh competing health risks from age-related medical conditions.